A Novel Platelet Concentrate: Titanium-Prepared Platelet-Rich Fibrin

Basit Öğe Kaydı
dc.contributor.authorTunali, Mustafa
dc.contributor.authorOzdemir, Hakan
dc.contributor.authorKucukodaci, Zafer
dc.contributor.authorAkman, Serhan
dc.contributor.authorYaprak, Emre
dc.contributor.authorToker, Hulya
dc.contributor.authorFiratli, Erhan
dc.date.accessioned2020-03-26T18:49:14Z
dc.date.available2020-03-26T18:49:14Z
dc.date.issued2014
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractWe developed a new product called titanium-prepared platelet-rich fibrin (T-PRF). The T-PRF method is based on the hypothesis that titanium may be more effective in activating platelets than the silica activators used with glass tubes in Chouckroun's leukocyte- and platelet-rich fibrin (L-PRF) method. In this study, we aimed to define the structural characteristics of T-PRF and compare it with L-PRF. Blood samples were collected from 10 healthy male volunteers. The blood samples were drawn using a syringe. Nine milliliters was transferred to a dry glass tube, and 9 mL was transferred to a titanium tube. Half of each clot (i.e., the blood that was clotted using T-PRF or L-PRF) was processed with a scanning electron microscope (SEM). The other half of each clot was processed for fluorescence microscopy analysis and light microscopy analysis. The T-PRF samples seemed to have a highly organized network with continuous integrity compared to the other L-PRF samples. Histomorphometric analysis showed that T-PRF fibrin network covers larger area than L-PRF fibrin network; also fibrin seemed thicker in the T-PRF samples. This is the first human study to define T-PRF as an autogenous leukocyte-and platelet-rich fibrin product. The platelet activation by titanium seems to offer some high characteristics to T-PRF.en_US
dc.description.sponsorshipScientific Research Project Coordination Center of the Gulhane Military Medical Academyen_US
dc.description.sponsorshipThe authors affirm that they have no financial affiliation (e.g., employment, direct payment, stock holdings, retainers, consultantships, patent licensing arrangements, or honoraria) or involvement with any commercial organization with direct financial interest in the subject or materials discussed in this paper, nor have any such arrangements existed in the past three years. Any other potential conflict of interests is disclosed. This study was supported by the Scientific Research Project Coordination Center of the Gulhane Military Medical Academy.en_US
dc.identifier.doi10.1155/2014/209548en_US
dc.identifier.issn2314-6133en_US
dc.identifier.issn2314-6141en_US
dc.identifier.pmid24563860en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://dx.doi.org/10.1155/2014/209548
dc.identifier.urihttps://hdl.handle.net/20.500.12395/30561
dc.identifier.wosWOS:000330672200001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherHINDAWI LTDen_US
dc.relation.ispartofBIOMED RESEARCH INTERNATIONALen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.titleA Novel Platelet Concentrate: Titanium-Prepared Platelet-Rich Fibrinen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu